कंपनी का अवलोकन
CollPlant Biotechnologies Ltd. operates within the healthcare sector, specifically focusing on the biotechnology industry through its specialized work in regenerative and aesthetic medicine. The company's core business involves the development and commercialization of three-dimensional (3D) bioprinting technologies for tissues and organs, alongside medical aesthetics solutions deployed across the United States, Canada, Israel, Europe, and international markets. These products are fundamentally grounded in recombinant human collagen science, aiming to address critical needs in tissue regeneration and cosmetic procedures. In terms of market scale, CollPlant Biotechnologies Ltd. holds a market capitalization of $5.54M and employs a workforce of 39 individuals to generate annual revenue of $2.37M. These financial figures indicate that the company functions as a small-cap entity with a relatively limited operational footprint compared to large-scale pharmaceutical peers, suggesting a stage where resources are heavily concentrated in research and development rather than mature profit generation.
वित्तीय स्वास्थ्य
The company reported revenue of $2.37M over the trailing twelve months, yet recorded a net income of $-11,489,000 and an EBITDA of $-10,571,000. The substantial negative gap between the positive revenue of $2.37M and the significant net loss of $-11,489,000 reveals a cost structure where operating expenses, likely driven by R&D and clinical trial costs, far exceed gross profit generation. Free cash flow stands at $-5,480,875, which indicates that the company is currently burning cash to fund its operations and growth initiatives rather than generating surplus liquidity for reinvestment or shareholder returns. Gross margin is reported at 64.8%, suggesting that the cost of goods sold is well-controlled relative to sales, though this high margin is insufficient to cover broader operational burn rates. Conversely, the operating margin is -5250.0% and the profit margin is 0.0%, levels that highlight severe inefficiencies in covering fixed costs and administrative overheads relative to the revenue base. The company holds $5.59M in cash against $2.85M in debt, resulting in a debt-to-equity ratio of 46.80, which presents a leveraged balance sheet where liabilities are more than four times the equity base. Despite the leverage, the current ratio of 2.52 indicates a strong short-term liquidity position, as current assets are more than twice the current liabilities, ensuring the ability to meet obligations due within a year. Return on Equity is -117.6% and Return on Assets is -48.7%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate profit in the absence of profitable operations.
मूल्यांकन आकलन
The valuation metrics present a complex picture for a loss-making entity, with a trailing P/E ratio of N/A and a forward P/E of -0.98. The negative forward P/E implies that the market prices in expectations of continued losses or a turnaround that has not yet materialized in earnings per share, making traditional earnings-based valuation methods inapplicable. The price-to-book ratio is 0.81, indicating that the market values the company at less than its net asset value, which often suggests a market discount for the risks associated with the biotechnology sector and lack of current profitability. Alternative valuation multiples such as the price-to-sales ratio of 2.33 and an EV/EBITDA of -0.26 provide different perspectives; the P/S ratio suggests investors are willing to pay a premium for sales volume, while the negative EV/EBITDA reflects the company's inability to generate earnings before interest, taxes, depreciation, and amortization. The stock's trading range over the last year spans a 52-week high of $4.98 and a 52-week low of $0.34, placing the current valuation context within a highly volatile band. The beta value is 0.94, which signifies that the stock's price volatility moves in tandem with the broader market, lacking the defensive characteristics of non-correlated assets or the high leverage of speculative biotech stocks.
Growth & Income
Revenue growth year-over-year has contracted significantly to -63.4%, while earnings growth is N/A due to the company's lack of profitability. The decline in revenue indicates a contraction in the business model or sales channels, and since earnings are negative, the relationship between revenue contraction and earnings is not linear in the traditional sense of margin expansion. CollPlant Biotechnologies Ltd. is not a dividend payer, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company does not distribute cash to shareholders but instead retains any available liquidity, although in this specific period, cash reserves are being depleted to fund operations. This non-dividend status aligns with the typical lifecycle of a biotechnology firm that prioritizes capital expenditure and research investment over income distribution. Overall, the growth and income profile is characterized by negative revenue momentum, a complete absence of dividend income, and a reliance on cash reserves to sustain operations amidst significant losses.